The Pharmacy Quality Assurance Commission (PQAC) held an emergency meeting to discuss the Medical Quality Assurance Commission’s (MQAC) request seeking a formal Attorney General’s Opinion regarding the use of the term “diagnosis” in a Collaborative Drug Therapy Agreement. Pharmacists, practitioners, or patients currently utilizing a Collaborative Drug Therapy Agreement may also wish to submit comment. Note that you must notify the Attorney General by Friday, July 13that you intend to provide comment. The Attorney General’s Office will then provide information on how and when the comments should be submitted. If you would like, the PQAC would appreciate a copy of the comments you submit to the Attorney General. These can be copied to the PQAC email address.

For more information, contact NACDS’ Sandra Guckian at 703-774-4801.

Engrossed Substitute—ESHB 1047—has been signed by Gov. Jay Inslee (D), creating a statewide, voluntary, drug take-back program, funded by manufacturers. The newly enacted legislation also includes local pre-emption and sunsets in 2029.

For more information, contact NACDS’ Sandra Guckian at 703-774-4801.

Engrossed Substitute – ESHB 1047 unanimously passed the Senate. Although it will have to go back to the House of Representatives for concurrence on a technical amendment made in the Senate, it is anticipated the bill will be signed into law by Gov. Jay Inslee (D), creating a statewide, voluntary, drug take-back program, funded by manufacturers. The bill includes local pre-emption and sunsets in 2029, if not reconfirmed by the state legislature.

For more information, contact NACDS’ Sandra Guckian at 703-774-4801.

NACDS submitted a letter to the members of the Washington State House of Representatives Health Care and Wellness Committee in support of the State Department of Health’s legislation removing a burdensome, antiquated requirement that all e-prescribing systems be approved by the Pharmacy Quality Assurance Commission, formerly the Board of Pharmacy.